Printer Friendly

Advanced Medical Optics Announces Voluntary Recall of 18 Lots of Complete(R) MoisturePLUS(TM) Contact Lens Care Products Distributed and Sold in the U.S.

Includes Certain Lots of 12-Ounce Bottles and Active Packs

SANTA ANA, Calif., Nov. 21 /PRNewswire-FirstCall/ -- Advanced Medical Optics, Inc. (AMO) , a global ophthalmic surgical and eye care products company, today announced a nationwide, voluntary recall of certain lots of its 12-ounce COMPLETE(R) MoisturePLUS(TM) multipurpose contact lens care solution and Active Packs. Three lots sold in Japan were found to have bacterial contamination, which compromised sterility. Because of this production-line issue at its manufacturing plant in China, AMO is recalling 18 lots distributed in the U.S. that were manufactured on the same production lines during the same production period. Non-sterility of a contact lens solution may have serious health consequences, including eye infection and microbial keratitis. AMO has not received any reports of adverse health events associated with the recalled product lots in the U.S.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050324/AMOLOGO )

Lot numbers are located on the top of the product box and on the side of the product bottle. The recalled product lots include:
 Bottled Lot
 Package Lot No. Product Description Number(s) in Kit
 ZB03087 COMPLETE MoisturePLUS Active Pack ZB03085, ZB02845
 ZB03724 COMPLETE MoisturePLUS Active Pack ZB03713, ZB03506
 ZB03734 COMPLETE MoisturePLUS Active Pack ZB03713, ZB03506
 ZB03735 COMPLETE MoisturePLUS Active Pack ZB03713, ZB03510
 ZB03736 COMPLETE MoisturePLUS Active Pack ZB03713, ZB03510
 ZB03739 COMPLETE MoisturePLUS Active Pack ZB03737, ZB03510
 ZB02710 COMPLETE MoisturePLUS 12oz (360 mL) ZB02709
 ZB02714 COMPLETE MoisturePLUS 12oz (360 mL) ZB02713
 ZB02718 COMPLETE MoisturePLUS 12oz (360 mL) ZB02717
 ZB02722 COMPLETE MoisturePLUS 12oz (360 mL) ZB02721
 ZB02746 COMPLTE MoisturePLUS 2 X 12 oz ZB02745
 ZB02750 COMPLETE MoisturePLUS 2 X 12 oz ZB02749
 ZB02771 COMPLETE MoisturePLUS 2 X 12 oz ZB02770
 ZB02792 COMPLETE MoisturePLUS 2 X 12 oz ZB02791
 ZB02796 COMPLETE MoisturePLUS 2 X 12 oz ZB02795
 ZB02800 COMPLETE MoisturePLUS 2 X 12 oz ZB02799
 ZB02804 COMPLETE MoisturePLUS 2 X 12 oz ZB02803
 ZB03535 COMPLETE MoisturePLUS 2 X 12 oz ZB03534






Contact lens users who experience symptoms of an eye infection such as redness, pain, tearing, increased light sensitivity, blurry vision, discharge or swelling, should remove their lenses and consult their eye care provider immediately.

Consumers who believe they are in possession of the recalled product should discontinue use immediately and call 1-877-884-7779 Monday through Friday between 8 a.m. and 5 p.m. Eastern Time or visit http://www.amo-inc.com/ for instructions. The company is currently contacting retailers, customers and distributors regarding return and replacement instructions. Reply cards and mailing slips are being provided for return of product. Retailers may also call 1-877-884-7779 Monday through Friday from 8 a.m. through 5 p.m. Eastern Time for more information.

Please report any adverse reactions experienced with the use of this product and/or quality problems to AMO by calling 1-calling 1-800-347-5005 and to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, HF-2, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch Web site at http://www.fda.gov/medwatch.

Product from the recalled lots was distributed nationwide to food, drug and mass merchandiser accounts. The recall does not include 4-ounce and 16-ounce bottles, or professional samples and packs provided to eye care practitioners.

The U.S. recall includes approximately 183,000 units, representing less than one percent of COMPLETE(R) MoisturePLUS(TM) contact lens products distributed in the U.S. on an annual basis. Based on its investigation to date, AMO believes the likelihood of users experiencing an adverse reaction is low. However, the company is taking a conservative approach and is conducting the recall in the best interest of its customers.

The company commenced the investigation after testing of products sold in Japan determined that three production lots were found to be non-sterile and contaminated with bacteria. As a result, AMO conducted a limited product withdrawal in Japan and notified appropriate global regulatory authorities, including the FDA. The subsequent investigation traced the manufacturing issue to two of the four production lines in its China facility that manufactured product during a specific period. This product was shipped to the U.S., Japan and Asia Pacific and is now the subject of this recall. AMO has temporarily ceased all manufacturing at the China facility and scheduled a special cleaning and sanitation of the manufacturing areas and all applicable equipment.

Products manufactured in AMO's facility in Spain, which produces the vast majority of AMO's contact lens solution products distributed in the U.S. and Europe, are not affected by this recall.

"AMO is committed to taking all necessary measures to remedy this production-line issue and protect the trust physicians and patients place in our products," said Randy Meier, executive vice president, operations; president, global eye care and chief financial officer. "COMPLETE(R) MoisturePLUS(TM) products have been used safely by millions of contact lens wearers since their introduction in 2003 and are supported by our 50-year heritage of meeting high safety and efficacy standards."

Forward-Looking Statements

This press release contains forward-looking statements about AMO, including those relating to the product, AMO's investigation, AMO's proposed corrective actions based thereon, and other statements of AMO's current beliefs. All forward-looking statements in this press release are based on estimates and assumptions and represent AMO's judgment only as of the date of this press release. Actual results may differ from current expectations based on a number of factors including but not limited to, AMO's ongoing investigation of the root cause, interactions with global regulatory authorities, the scope of the recall, and unforeseen health and safety issues. Therefore, the reader is cautioned not to rely on these forward-looking statements. AMO disclaims any intent or obligation to update these forward-looking statements.

Additional information concerning these and other risk factors may be found in previous financial press releases issued by AMO and AMO's public periodic filings with the Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in AMO's 2005 Form 10-K filed in March 2006 and quarterly report on Form 10-Q filed in November 2006. Copies of press releases and additional information about AMO are available at http://www.amo-inc.com/, or by contacting AMO's Investor Relations Department by calling 714-247-8290.
 Investors:
 Sheree Aronson
 (714) 247-8290
 sheree.aronson@amo-inc.com

 Media:
 Deborah Kazenelson Deane
 Edelman Public Relations
 (323) 202-1064
 Deborah.Kazenelson@edelman.com

 Jackie Quintanilla
 Edelman Public Relations
 (323) 202-1053
 jacqueline.quintanilla@edelman.com



CONTACT: Investors, Sheree Aronson, +1-714-247-8290, sheree.aronson@amo-inc.com; or Media, Deborah Kazenelson Deane, +1-323-202-1064, Deborah.Kazenelson@edelman.com, or Jackie Quintanilla, +1-323-202-1053, jacqueline.quintanilla@edelman.com, both of Edelman Public Relations, for Advanced Medical Optics, Inc.

Web site: http://www.amo-inc.com/
COPYRIGHT 2006 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 21, 2006
Words:1099
Previous Article:Columbia County Residents to Benefit From Verizon Wireless Network Expansion.
Next Article:China Biopharmaceuticals Holdings Initiates Clinical Trials of Sofalcone for Treatment of Digestive Ulcers.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters